Mucositis Therapeutics - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for mucositis therapeutics including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, and target.

Overview of the drug development pipeline for mucositis therapeutics

Mucositis is the inflammation of the mucous membranes, which is generally due to the side effects of cancer radiotherapy and chemotherapy. Mucositis is painful, and it occurs in the gastrointestinal tract. The mucosal tissue is the most sensitive tissue in the human body, and the cancer treatment leaves it open, which tends to build up the infection, and the mucosal tissue starts getting inflamed. Oral mucositis is when the inflammation and the ulceration occur in the mouth while it can spread across the whole gastrointestinal tract, adversely affecting the digestive system. The degree of mucositis depends upon the severity. However, high-dose radiotherapy and chemotherapy are the major causes of severe mucositis. According to the CDC, Loyola University Medical Center, in 2005, reported that 40% of the total patients who received standard-dose chemotherapy were diagnosed with mucositis. Similarly, 80% of the total patients who received radiation therapy for head and neck cancer and 75% of the total patients who underwent bone marrow transplantation were also diagnosed with mucositis. As a result, with rising incidences of the disease, the drug development for mucositis therapeutics is expected to increase considerably in the forthcoming years.

According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for mucositis therapeutics. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of mucositis therapeutics. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Aldeyra Therapeutics
• BIOCND
• CelaCare Technologies
• EpicentRx
• Manopar Therapeutics

Therapeutic assessment of the drug development pipeline for mucositis therapeutics by route of administration

• Oral
• Intravenous
• Oral + intravenous

The oral route of administration (ROA) involves the application of the drug directly into the mouth cavity, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for mucositis therapeutics by therapy

• Monotherapy
• Combination therapy

According to this pipeline analysis report, most of the molecules that are currently in the drug development pipeline for mucositis therapeutics are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug molecules in the various development stages for mucositis therapeutics?
• What are the companies that are currently involved in the development of drug molecules for mucositis therapeutics?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.